Search or
𝛼SK
𝛼SKbearish
Everest Medicine Placement - Third Deal in the Year, Previous Ones Didn’t Do Well
501 Views24 Jul 2025 19:25
Everest Medicines (1952 HK) aims to raise around US$200m via a top-up placement. In this note, we run the deal through our framework and talk about other deal dynamics.
What is covered in the Full Insight:
- Introduction
- Deal Overview and Past Performance
- Company and Financial Overview
- Clinical Trials and Developments
- Conclusion and Recommendations
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
x